Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Attorney Stuart Silverman says the First Circuit’s widening the divide on the False Claims Act’s causation standard adds to the need for the Supreme Court to weigh in.
Shares of Regeneron Pharmaceuticals Inc. REGN slid 3.58% to $718.16 Tuesday, on what proved to be an all-around grim trading ...
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.
Celestial discoveries: Paz won the $250,000 top prize for his research on detecting objects in the night sky. Using ...